Literature DB >> 26833358

Developmental status of preschool children receiving cART: a descriptive cohort study.

J Potterton1, N Hilburn1, R Strehlau2.   

Abstract

BACKGROUND: HIV is known to cause neurodevelopmental problems in infants and young children. The impact of HIV on the development of preschool-age children has been less well described.
METHOD: The study was conducted at an urban paediatric HIV clinic in Johannesburg, South Africa. A sample of convenience was used. Sixty-eight medically stable children between the ages of 3 and 5 years were assessed with the Griffiths Scales of Mental Development. Children were excluded from the study if they had severe HIV encephalopathy, which made it impossible for them to participate in the items on the Griffiths Scales of Mental Development.
RESULTS: The children had started combination antiretroviral treatment (cART) at a mean age of 8.1 months. The majority of the children were virologically suppressed and did not present with wasting or stunting. Severe overall developmental delay (z-scores < -2SD) was detected in 55.88% of children. Developmental facets related to speech, cognition and perception were the most severely affected. Personal-social development was the least affected with only 13.4% of the children demonstrating severe delay.
CONCLUSION: Despite having early access to cART, children infected with HIV are still at risk for severe developmental delay across a number of facets. Very early initiation of cART may help alleviate this problem. All preschool children infected with HIV should have routine developmental screening.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  HIV; children; developmental delay; neurodevelopment; preschool

Mesh:

Substances:

Year:  2016        PMID: 26833358     DOI: 10.1111/cch.12321

Source DB:  PubMed          Journal:  Child Care Health Dev        ISSN: 0305-1862            Impact factor:   2.508


  4 in total

1.  Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life.

Authors:  Barbara Laughton; Shalena Naidoo; Els F M T Dobbels; Michael J Boivin; Anita Janse van Rensburg; Richard H Glashoff; Gert U van Zyl; Mariana Kruger; Mark F Cotton
Journal:  South Afr J HIV Med       Date:  2019-10-30       Impact factor: 2.744

2.  Cognitive outcomes at ages seven and nine years in South African children from the children with HIV early antiretroviral (CHER) trial: a longitudinal investigation.

Authors:  Kaylee S van Wyhe; Barbara Laughton; Mark F Cotton; Ernesta M Meintjes; Andre Jw van der Kouwe; Michael J Boivin; Martin Kidd; Kevin Gf Thomas
Journal:  J Int AIDS Soc       Date:  2021-07       Impact factor: 5.396

3.  Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy.

Authors:  Paul Bangirana; Theodore D Ruel; Michael J Boivin; Satish K Pillai; Leila B Giron; Alla Sikorskii; Asish Banik; Jane Achan
Journal:  J Int AIDS Soc       Date:  2017-10       Impact factor: 5.396

4.  A Feasibility RCT Evaluating a Play-Informed, Caregiver-Implemented, Home-Based Intervention to Improve the Play of Children Who Are HIV Positive.

Authors:  Elelwani Ramugondo; Anande Ferreira; Donna Chung; Reinie Cordier
Journal:  Occup Ther Int       Date:  2018-12-19       Impact factor: 1.448

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.